Canaccord raised the firm’s price target on Biogen (BIIB) to $230 from $220 and keeps a Buy rating on the shares. The firm said they reported its 4Q25 results where revenue/adj. EPS came in at $2.28bn/$1.99 and easily beat consensus. Canaccord continues to view the company as undervalued and raise the target on better margins while viewing Leqembi as underappreciated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $177 from $157 at Piper Sandler
- Biogen price target raised to $246 from $185 at Guggenheim
- Biogen, Eisai say BLA for Leqembi accepted for Priority Review by NMPA of China
- Biogen price target raised to $201 from $191 at Bernstein
- Biogen price target raised to $228 from $194 at H.C. Wainwright